TR199800156T1 - �ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi. - Google Patents

�ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi.

Info

Publication number
TR199800156T1
TR199800156T1 TR1998/00156T TR9800156T TR199800156T1 TR 199800156 T1 TR199800156 T1 TR 199800156T1 TR 1998/00156 T TR1998/00156 T TR 1998/00156T TR 9800156 T TR9800156 T TR 9800156T TR 199800156 T1 TR199800156 T1 TR 199800156T1
Authority
TR
Turkey
Prior art keywords
dose
low
dosage forms
preparation process
drugs
Prior art date
Application number
TR1998/00156T
Other languages
English (en)
Turkish (tr)
Inventor
Albert Napper James
Triona O'brien Karen
James Manek Sultan
Kumar Rajinder
Mary Loudon Julia
Sidney George Clark Michael
Mortimer Neil
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9515624.6A external-priority patent/GB9515624D0/en
Priority claimed from GBGB9606684.0A external-priority patent/GB9606684D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of TR199800156T1 publication Critical patent/TR199800156T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TR1998/00156T 1995-07-29 1996-07-29 �ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi. TR199800156T1 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9515624.6A GB9515624D0 (en) 1995-07-29 1995-07-29 Novel process
GBGB9606684.0A GB9606684D0 (en) 1996-03-29 1996-03-29 Novel process

Publications (1)

Publication Number Publication Date
TR199800156T1 true TR199800156T1 (xx) 1998-04-21

Family

ID=26307485

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/00156T TR199800156T1 (xx) 1995-07-29 1996-07-29 �ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi.

Country Status (25)

Country Link
EP (1) EP0841902A2 (fr)
JP (1) JPH11510493A (fr)
KR (1) KR19990035972A (fr)
CN (1) CN1196677A (fr)
AP (1) AP858A (fr)
AR (1) AR004178A1 (fr)
AU (1) AU716961B2 (fr)
BG (1) BG102266A (fr)
BR (1) BR9609804A (fr)
CA (1) CA2228048A1 (fr)
CZ (1) CZ24798A3 (fr)
DZ (1) DZ2077A1 (fr)
EA (2) EA199901055A1 (fr)
HU (1) HUP9900521A3 (fr)
IL (1) IL122897A0 (fr)
MA (1) MA23953A1 (fr)
MX (1) MX9800809A (fr)
NO (1) NO980384L (fr)
NZ (1) NZ315632A (fr)
OA (1) OA10659A (fr)
PL (1) PL325242A1 (fr)
SK (1) SK11098A3 (fr)
TR (1) TR199800156T1 (fr)
UY (1) UY24297A1 (fr)
WO (1) WO1997004750A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619074D0 (en) * 1996-09-12 1996-10-23 Smithkline Beecham Plc Composition
IL138192A0 (en) 1998-03-11 2001-11-25 Smithkline Beecham Plc Controlled release oral dosage forms
FR2796840B1 (fr) * 1999-07-26 2003-06-20 Ethypharm Lab Prod Ethiques Comprimes faiblement doses et procede de preparation
US7867990B2 (en) 2000-12-14 2011-01-11 Ortho-Mcneil Pharmaceutical, Inc. Steroid hormone products and methods for preparing them
WO2005097076A2 (fr) * 2004-04-09 2005-10-20 Smithkline Beecham Corporation Produits pharmaceutiques a faibles doses
WO2026018154A1 (fr) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Associations de sabcoméline et d'antagonistes muscariniques ne pénétrant pas dans le snc
WO2026018155A1 (fr) 2024-07-16 2026-01-22 Syremis Therapeutics Ltd. Combinaisons de sabcoméine avec des antagonistes muscariniques pénétrant dans le système nerveux non central à action prolongée

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4489026A (en) * 1982-09-07 1984-12-18 The Upjohn Company Process for preparing solid unit dosage forms of ultra-low dose drugs
JPS5970614A (ja) * 1982-10-14 1984-04-21 Asahi Chem Ind Co Ltd 微量主薬系湿式固形製剤方法
US4898736A (en) * 1988-03-09 1990-02-06 Merck & Co., Inc. Method for tablet preparation
DK0392803T3 (da) * 1989-04-13 2004-10-18 Beecham Group Plc Hidtil ukendte forbindelser
ZA939565B (en) * 1993-12-21 1994-08-11 Applied Analytical Ind Inc Method for preparing low dose pharmaceutical products.

Also Published As

Publication number Publication date
IL122897A0 (en) 1998-08-16
EA000740B1 (ru) 2000-02-28
JPH11510493A (ja) 1999-09-14
WO1997004750A3 (fr) 1997-03-27
BG102266A (en) 1998-10-30
SK11098A3 (en) 1998-07-08
AR004178A1 (es) 1998-11-04
CN1196677A (zh) 1998-10-21
PL325242A1 (en) 1998-07-06
DZ2077A1 (fr) 2002-07-22
BR9609804A (pt) 1999-07-06
MA23953A1 (fr) 1997-04-01
WO1997004750A2 (fr) 1997-02-13
HUP9900521A3 (en) 2001-04-28
MX9800809A (es) 1998-04-30
AP9801170A0 (en) 1998-01-31
NZ315632A (en) 1999-11-29
UY24297A1 (es) 1997-01-23
AU6738496A (en) 1997-02-26
KR19990035972A (ko) 1999-05-25
CZ24798A3 (cs) 1998-06-17
AU716961B2 (en) 2000-03-09
HUP9900521A2 (hu) 1999-06-28
OA10659A (en) 2002-09-18
EA199901055A1 (ru) 2000-06-26
EP0841902A2 (fr) 1998-05-20
NO980384L (no) 1998-03-26
NO980384D0 (no) 1998-01-28
AP858A (en) 2000-07-12
CA2228048A1 (fr) 1997-02-13
EA199800179A1 (ru) 1998-10-29

Similar Documents

Publication Publication Date Title
HK48392A (en) Drug particles having constant release and immediate release
NZ508526A (en) Opioid formulations for treating pain
WO2001019337A3 (fr) Formes et procedes pharmaceutiques permettant une therapie par la reboxetine efficace avec une seule administration quotidienne
MY118371A (en) Tetrahydrolipstatin containing compositions
PL306421A1 (en) Controlled release morphine salt containing preparation
EP1243267A3 (fr) Composition pharmaceutique contenant de l'amoxicilline et du clavulanate
Nielsen et al. Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group
TR199800156T1 (xx) �ok d���k dozlu ila�lar� kat� dozaj �ekillerinde haz�rlama prosesi.
IL135235A0 (en) Method and composition for preventing nephrotoxicity caused by cyclosporins and tacrolimus
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
PT891186E (pt) Administração nasal de agentes para o tratamento de emese tardia
ES2179729A1 (es) Forma farmaceutica solida de administracion oral dispersable en agua, que comprende rifampicina, isoniazida y piridoxina hidrocloruro, procedimiento para su obtencion y forma de presentacion de dicha forma farmaceutica.
EP0271151A3 (fr) Formes de dosage de l'azumolène
Maisano et al. Efficacy of two oral dose regimens of granisetron
Stern et al. Nifedipine plasma concentration in patients treated for angina pectoris
Bickel et al. Triple buprenorphine maintenance doses maintain opioid-dependent outpatients for 72 hours with minimal withdrawal
ATE85218T1 (de) Oral anzuwendende arzneiform zur einmal taeglichen behandlung der hypertonie mit diltiazemhydrochlorid.
Jonsson Development of long-acting nitrate delivery systems
GB9917290D0 (en) Pharmaceutical composition
DE69814669D1 (de) Pharmaceutische Zusammensetzung enthaltend (+)-EPHEDRIN und einen H1 Rezeptor Antagonisten
Lavický et al. Vibration stress and pharmacokinetics of rifampicin
ECSP961835A (es) Nuevo procedimiento
Feuerstein et al. Single drug therapy with sodium valproate in primary generalized epilepsy. Phase 2: Long term efficacy and tolerance study.
Borisova et al. The use of fenazid in patients with pulmonary tuberculosis with poor isoniazid tolerance
WO2001028566B1 (fr) Utilisation de l'acide acetyl salicilique dans le traitement de l'hyperplasie de la prostate benigne